Ipamorelin + CJC-1295 Stack: Evidence, Mechanism, and Protocol

How Each Peptide Works at the Receptor Level

Ipamorelin and CJC-1295 each stimulate growth hormone release, but they do so at completely different binding sites, which is precisely why the combination is pharmacologically coherent.

Ipamorelin: Selective GHSR-1a Agonism

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that binds the ghrelin receptor, formally known as the growth hormone secretagogue receptor type 1a (GHSR-1a) [1]. GHSR-1a is expressed on pituitary somatotrophs and in the hypothalamus. When ipamorelin binds this receptor, it triggers a Gq-protein cascade that depolarizes the somatotroph and releases GH from secretory granules.

The distinguishing feature of ipamorelin, compared with older GHRPs such as GHRP-2 and GHRP-6, is its selectivity. At pharmacological doses, ipamorelin does not measurably raise cortisol, prolactin, or ACTH in rat pituitary cell studies [2]. GHRP-6, by contrast, raises cortisol significantly via non-selective receptor cross-talk. That selectivity matters clinically because chronic cortisol elevation would counteract the anabolic intent of GH stimulation.

CJC-1295: GHRH Receptor Agonism with Extended Half-Life

CJC-1295 is a synthetic 30-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH 1-44). It binds the GHRH receptor (GHRHR) on pituitary somatotrophs, activating adenylyl cyclase via a Gs-protein, which raises intracellular cAMP and promotes GH secretion and somatotroph proliferation over time [3].

Two chemical forms exist in clinical use. CJC-1295 without DAC (also called modified GRF 1-29 or "mod GRF") has a half-life of roughly 30 minutes. CJC-1295 with DAC (Drug Affinity Complex) contains a maleimide-lysine side chain that covalently binds albumin in plasma, extending the half-life to approximately 6-8 days [4]. The published Phase II trial by Teichman et al. (2006, N=65) tested CJC-1295 with DAC and showed dose-dependent increases in mean GH concentrations of 1.5-to-3-fold and IGF-1 increases of 1.3-to-1.9-fold that persisted for up to 28 days after a single injection [4].

Why Two Different Receptors Matter

GHSR-1a and GHRHR are pharmacologically distinct. Stimulating only one receptor type produces a submaximal GH pulse. Endogenous GH secretion is itself a two-signal process: hypothalamic GHRH gates the pituitary's readiness, while ghrelin (the endogenous GHSR-1a ligand) provides the acute depolarizing signal. Replicating that two-signal architecture with exogenous peptides is the mechanistic basis for stacking a GHRH analogue with a GHRP [5].

Synergistic GH Release: What the Data Actually Show

The word "combination" is often used loosely in peptide circles. In this case, the mechanistic argument has quantitative animal-model support, though human RCT data for the combination remain absent.

Animal-Model Evidence

Bowers et al. Demonstrated in rat models that combining a GHRP with GHRH produced GH pulse amplitudes 4-to-10-fold greater than GHRH alone [5]. The effect was not simply additive. The GHRP component appeared to sensitize somatotrophs to GHRH by mobilizing intracellular calcium stores through the Gq pathway, while GHRH simultaneously elevated cAMP via Gs. The two second-messenger cascades converge on the same exocytosis machinery, producing a larger GH burst than either signal can generate independently.

A 2003 rodent study by Svensson et al. Confirmed that ipamorelin specifically, at 1 nmol/kg intravenous dose, raised GH plasma concentrations to levels comparable to those seen with GHRP-6 but without the cortisol co-elevation [2]. When ipamorelin was combined with GHRH in that model, the GH response was amplified beyond either monotherapy.

Human Evidence: Extrapolated, Not Direct

No published randomized controlled trial has tested the ipamorelin-plus-CJC-1295 combination in humans. The Teichman 2006 Phase II trial (N=65) established that CJC-1295 with DAC raises IGF-1 in healthy adults without serious adverse events at doses up to 60 mcg/kg [4]. Separate Phase I data for ipamorelin analogue compounds support safety in humans at doses below 300 mcg [6]. Practitioners who use this stack extrapolate from these single-agent human studies plus the animal combination data. That extrapolation is scientifically reasonable but not yet validated by a clinical trial.

This evidence gap must be stated plainly: patients and clinicians are operating on mechanistic inference, not a phase III efficacy dataset.

Pharmacokinetic Rationale for Co-Administration

The timing of injection matters because the two peptides operate on different pharmacokinetic timescales.

Matching Half-Lives to Clinical Goals

CJC-1295 without DAC has a half-life near 30 minutes, similar to ipamorelin's approximately 2-hour half-life when measured by GH response duration [3]. Co-injecting both at the same time means both receptor systems are activated in the same physiological window, mimicking the endogenous GHRH-ghrelin co-release that occurs at the hypothalamic level during natural GH pulses.

CJC-1295 with DAC is pharmacokinetically different. Its sustained albumin binding produces a tonic background elevation of GHRH-receptor stimulation that lasts days. Some practitioners inject the DAC form once weekly and then use ipamorelin two to three times daily on top of that background. That approach is theoretically sound but creates a non-pulsatile GH profile on the days between ipamorelin injections, which may reduce the amplitude of the somatotroph response to ipamorelin over time due to receptor desensitization [7].

Somatostatin Tone and Injection Timing

Endogenous somatostatin is the brake on GH secretion. Its concentration oscillates, reaching a nadir roughly every 3-4 hours in healthy adults [5]. Timing injections to this nadir (often described as the period 90-120 minutes after eating stops) may increase GH pulse amplitude. The supporting evidence is indirect, drawn from studies of endogenous GH pulsatility rather than from a protocol-specific trial [5, 8].

Standard Dosing Protocols in Clinical Use

The framework below reflects dosing ranges reported in the peer-reviewed literature for each single agent, combined with practitioner-reported protocols from telehealth settings. No trial has tested the exact combination doses listed here.

Protocol 1: CJC-1295 Without DAC Plus Ipamorelin (Most Common)

This is the format most compounding pharmacies supply as a pre-mixed vial.

• Ipamorelin: 100-300 mcg per injection
• CJC-1295 (no DAC / mod GRF 1-29): 100-300 mcg per injection
• Frequency: 1-3 injections daily, subcutaneous, ideally on an empty stomach or 90 minutes after the last meal and before sleep
• Cycle length: 12-24 weeks followed by a 4-to-8-week break to avoid GH receptor downregulation
• Injection site: Abdomen, approximately 1-2 inches from the navel, rotating sites each injection

The pre-sleep injection is prioritized because it coincides with the largest endogenous GH pulse, which occurs roughly 60-90 minutes after sleep onset and is tied to slow-wave sleep [8].

Protocol 2: CJC-1295 With DAC Plus Ipamorelin

• CJC-1295 with DAC: 1,000-2,000 mcg subcutaneous injection once weekly
• Ipamorelin: 200-300 mcg subcutaneous injection, 2x daily
• Cycle length: 12-16 weeks
• Monitoring: Fasting IGF-1 at baseline and at 8 weeks; fasting glucose at baseline and at 8 weeks

The weekly DAC injection raises the logistical burden less but creates the tonic stimulation concern described above. Some clinicians avoid the DAC form for this reason, reserving it for patients who find daily injections prohibitive.

Starting Conservatively

New users and patients over 50 should begin at 100 mcg of each peptide once nightly for 4 weeks before increasing frequency. IGF-1 should be checked before the dose escalation. An IGF-1 above the age-adjusted upper limit of normal (approximately 200-400 ng/mL in adults depending on age, per GH Research Society guidelines) is a signal to reduce dose, not increase it [9].

Safety Profile and Known Risks

Water Retention and Joint Discomfort

The most commonly reported adverse effects of GH-stimulating peptides are mild fluid retention and transient joint aching, consistent with the known side-effect profile of recombinant human GH (rhGH) therapy. These effects appear to be dose-related and generally resolve with dose reduction [10].

Glucose and Insulin Sensitivity

GH is counter-regulatory to insulin. Sustained GH elevation from any secretagogue may impair glucose tolerance. Patients with pre-existing insulin resistance or type 2 diabetes need fasting glucose and HbA1c monitoring before starting and every 8-12 weeks during a cycle. The American Diabetes Association notes that GH excess (as seen in acromegaly) causes frank diabetes in approximately 20-30% of patients [11], a caution that extends by mechanism to prolonged secretagogue use.

Oncologic Uncertainty

IGF-1 is a mitogenic signal. Epidemiological data show that individuals in the highest IGF-1 quartile carry a modestly elevated risk for certain cancers, including colorectal, breast, and prostate [12]. No trial has directly linked ipamorelin or CJC-1295 use to cancer. The concern is theoretical but not dismissible over multi-year use. The Endocrine Society's clinical practice guideline on GH deficiency states: "GH therapy is contraindicated in patients with active malignancy" [10].

The guideline language addresses therapeutic GH, not secretagogues, but the mechanistic concern is parallel.

FDA Regulatory Status

Neither ipamorelin nor CJC-1295 holds FDA drug approval for any indication. The FDA placed both peptides on its list of bulk drug substances that may not be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act in a 2023 proposed rule, citing insufficient evidence of clinical use and safety [13]. Clinicians and patients should verify the current compounding status with a licensed pharmacy and confirm prescriber compliance with state medical board rules.

Monitoring Markers During a Stack Cycle

Objective monitoring distinguishes responsible peptide use from unguided experimentation. The following labs are the minimum reasonable panel:

• IGF-1 (serum): Baseline, 8 weeks into cycle, 4 weeks post-cycle. Target: mid-range for age and sex, not above upper limit.
• Fasting glucose and HbA1c: Baseline and at 8 weeks.
• Fasting insulin: Baseline, to calculate HOMA-IR if glucose is borderline.
• Complete metabolic panel: Baseline for hepatic and renal function, since peptides are cleared renally and hepatically.
• Lipid panel: Baseline, because GH modulates lipid metabolism. Recombinant GH studies show reductions in LDL-C and total cholesterol [10], and similar directional changes are expected with secretagogues.

The GH Research Society recommends that IGF-1 levels during any GH-stimulating therapy remain within the age-normalized reference range to minimize overstimulation risk [9]. That standard applies logically to secretagogue protocols even though the guideline was written for rhGH.

What Practitioners and Researchers Say

"The combination of a GHRH analogue with a GHRP represents the most physiologically coherent approach to stimulating GH secretion because it recapitulates the dual hypothalamic signals that govern pituitary somatotroph activity." This framing comes from the foundational GHRP pharmacology review by Bowers (2012), which synthesized three decades of secretagogue research [5].

Teichman et al. Wrote of CJC-1295: "Once- or twice-monthly injections may be a convenient and effective way to achieve sustained, physiologically relevant increases in GH and IGF-I levels" [4]. That description frames a DAC-based protocol as a background platform onto which a faster-acting agent like ipamorelin can logically be layered for acute pulse augmentation.

Evidence Quality Summary

Honest appraisal of the evidence hierarchy for this stack:

| Claim | Evidence Level | |---|---| | Ipamorelin raises GH via GHSR-1a | Strong: mechanistic + animal + human Phase I | | CJC-1295 raises GH and IGF-1 in humans | Moderate: Phase II RCT (N=65) | | Combination produces synergistic GH pulses | Moderate in animals; not tested in humans | | Protocol timing (fasted, pre-sleep) optimizes response | Indirect: inferred from GH pulsatility physiology | | 12-24-week cycle prevents desensitization | Expert opinion; no trial data | | Stack improves body composition or performance | No published human trial; patient-reported only |

Practitioners who prescribe this combination are making a judgment call grounded in mechanistic coherence and extrapolated single-agent data. That is different from evidence-based medicine in the classical sense, and patients deserve that distinction stated plainly before they start a cycle.